Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy
Synchronized spectrofluorimetric determination of ponatinib and curcumin as an effective therapeutic combination in laboratory prepared mixtures and human plasma samples
Graphical abstract
Introduction
Leukemia is a blood cell malignant disorder that occurs because of gene-promoting growth mutations. This abnormality triggers the development of immature blood cells in the bone marrow. The four primary forms of leukemia are chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), acute lymphocytic leukemia (ALL), and acute myeloid leukemia (AML) [1].
CML is triggered by gene aberration because there is DNA interchange between long arms of two different chromosomes 9 and 22, contributing to breakpoint cluster region (BCR-ABL) gene expression [2], [3]. In the chronic stage of CML, a tyrosine kinase inhibitor (TKI)-based therapy such as ponatinib is recommended.
Ponatinib (PON) Fig. 1(A) is a benzanilide substituted drug with a molecular formula of C29H27F3N6O. It is an effective, orally active TKI that is widely utilized in the treatment of resistant CML and Philadelphia chromosome positive acute lymphoblastic leukemia. It exerts its action via inhibition of tyrosine kinase activity of ABL and T315I mutant kinases [4]. A carbon–carbon triple bond in its structure was designed to target the T315I point mutation within the kinase domain of BCR-ABL [5]. In the literature survey of PON, few methods have been reported for its quantification such as spectrofluorimetry [6] and HPLC [7], [8], [9], [10], [11].
Despite the advanced treatment choices available for leukemia, unique therapeutic strategies are still required. Chemotherapy has a serious impact on human health, causing medical complications such as heart problems, immune loss and the damage of liver and neurons. Because chemotherapeutic agents affect both abnormal cells and normal cells, it causes many unwanted side effects as loss of hair, appetite besides mouth sores, diarrhea, nausea and vomiting [2].
Curcuminoids, which are natural compounds, are used in a variety of leukemia treatments. Curcumin has gained popularity in recent years, not only as a food additive but also as a vital medicine [2].
Curcumin (CUR) Fig. 1(B) is the active ingredient localized in Curcuma longa rhizome. It has powerful tyrosine kinase activity [12]. It was identified also as a bioactive compound have antibacterial, anti-inflammatory, anti-diabetic, antioxidant, cholesterol lowering activity [13], [14], [15]. Additionally, it has anti-platelet aggregation, anti-carcinogenic and chemo-preventive property [16]. CUR is an impressive compound that can enhance the treatment of CML patients in combination with typical TKI such as ponatinib as it triggered the up-regulation of miR-196b and reduced BCR-ABL at the level of mRNA and protein, resulting in leukemic cell growth inhibition [17].
Not only curcumin is effective in conjunction with chemotherapy but also, it is indicated for chemoprevention [18].
Several methods have been reported in the literature for the determination of CUR such as spectrophotometry [19], [20], [21] spectrofluorimetry [22], [23], electrochemical methods [24], [25], [26], [27], [28], and HPLC [29], [30], [31], [32], [33].
To date, no method for the simultaneous quantification of PON and CUR as co-administered drugs in biological fluids has been documented. This necessitates establishment of a responsive procedure for simultaneous estimation of both drugs for their therapeutic drug monitoring. Applying conventional spectrofluorimetric approach, the normal emission fluorescence spectra of the two studied drugs are strongly overlapped, and therefore this method did not contribute to the resolution of such mixture. The problem of spectral overlapping was solved using constant wavelength synchronous spectrofluorimetric approach. Upon applying this method, both PON and CUR have separated synchronous fluorescence emission peaks with intensities measurable at 303 and 412 nm, respectively. The spectrofluorimetric approach is distinguished by its sensitivity and selectivity, but selectivity concerns can arise owing to the overlap of the broad band spectrum mostly during analysis of multi-component samples. This overlapping problem could be solved by applying synchronous fluorescence spectroscopy (SFS) which has several virtues over conventional fluorescence method including clear spectra, high selectivity and minimal interference [34], [35], [36]. SFS behaves as a very simple and powerful method for quantitative evaluation of drugs studied in a single run within a reasonable time due to its sharp and narrow spectrum [37], [38], [39], [40], [41]. Based on the chemical properties of the studied drugs and their high therapeutic utility in the treatment of myeloid leukemia, the SFS technique was introduced for their synchronized estimation in spiked human plasma for the purpose of their therapeutic drug monitoring.
Section snippets
Instrumentation
- -
The spectrofluorimetric measurements were carried out using an Agilent G8900A Cary Eclipse Spectrofluorimeter (Agilent, California, USA) supplied with a Xenon flash lamp.
- -
For conducting the study, the synchronous mode was adjusted at Δλ = 160 nm, the slit width was adjusted at 5 nm and for smoothing of the resulting spectra, the factor 20 was used. The voltage was 800 V with 600 nm/min scanning rate in the range of 200–600 nm.
- -
pH was adjusted using P-901, Consort pH-meter.
- -
Vortex mixer (IVM-300P,
Results and discussion
With respect to the impact of SFS for the evaluation and implementation of many overlapping drugs, a highly sensitive and selective spectrofluorimetric approach for the analysis of PON and CUR in plasma of chronic myeloid patients was developed.
The spectrum of PON and CUR shows high native fluorescence intensity in ethanol either at 465 or 535 nm following excitation at 300 or 420 nm, respectively, as shown in Fig. 2.
Referring to Fig. 2, it was noticed that, PON and CUR emission spectra are
Conclusion
Curcumin is commonly prescribed with ponatinib to reduce side effect associated with chemotherapeutic agent. Quantification of both medications is a very important and crucial phase in the treatment protocols, necessitating therapeutic drug monitoring. This study uses a highly green sensitive synchronous spectrofluorimetric approach to analyze both medications simultaneously without interference from plasma endogenous components. With the green virtue of employing ethanol as an environmentally
Novelty statement
The paper is the first report on synchronous spectrofluorimetric method for the simultaneous determination of ponatinib and curcumin in laboratory prepared mixtures and human plasma.
CRediT authorship contribution statement
Mona E. El Sharkasy: Methodology, Software, Writing - review & editing. Rasha Abo Shabana: Data curation, Validation, Writing - review & editing. F. Belal: Supervision, Validation, Writing - review & editing. M. Walash: Supervision, Validation, Writing - review & editing. Manar M. Tolba: Supervision, Validation, Writing - review & editing.
Declaration of Competing Interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
References (47)
- et al.
Liquid chromatography–tandem mass spectrometric assay for ponatinib and N-desmethyl ponatinib in mouse plasma
J. Chromatogr. B
(2016) - et al.
Therapeutic drug monitoring of ponatinib using a simple high-performance liquid chromatography method in Japanese patients
Leukemia Res.
(2018) - et al.
Individual and simultaneous electrochemical determination of metanil yellow and curcumin on carbon quantum dots based glassy carbon electrode
Mater. Sci. Eng. C
(2018) - et al.
Stability indicating HPLC–UV method for detection of curcumin in Curcuma longa extract and emulsion formulation
Food Chem.
(2015) - et al.
A validated stability-indicating HPLC method for simultaneous determination of Silymarin and Curcumin in various dosage forms
Arabian J. Chem.
(2017) - et al.
Recent developments in multi-component synchronous fluorescence scan analysis
Trends Anal. Chem.
(2002) - et al.
Simultaneous determination of elbasvir and grazoprevir in their pharmaceutical formulation by synchronous fluorescence spectroscopy coupled to dual wavelength method
Spectrochim. Acta A
(2021) - et al.
Application of different spectrofluorimetric methods for determination of lesinurad and allopurinol in pharmaceutical preparation and human plasma
Spectrochim. Acta A
(2021) A new tool for the evaluation of the analytical procedure: Green Analytical Procedure Index
Talanta
(2018)- et al.
Oral health status in adult patients with newly diagnosed acute leukemia
Clin. Oral investig.
(2018)
Molecular targets of curcumin and future therapeutic role in leukemia
J. Biosci. Med.
Chronic myelogenous leukemia: biology and therapy
Ann. Intern. Med.
Ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute leukemia: recommendations of a German expert consensus panel with focus on cardiovascular management
Acta Haematol.
Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies
Onco Targets Ther.
Micellar enhanced spectrofluorimetric method for the determination of ponatinib in human plasma and urine via cremophor RH 40 as sensing agent
Int. J. Anal. Chem.
Validated LC-MS/MS method for the quantification of ponatinib in plasma: application to metabolic stability
PLoS One
Simple determination of plasma ponatinib concentration using HPLC
Biol. Pharm. Bull.
Development and validation of a simultaneous quantification method of 14 tyrosine kinase inhibitors in human plasma using LC-MS/MS
Ther. Drug Monit.
Curcumin as tyrosine kinase inhibitor in cancer treatment
Eur. J. Med. Chem.
Curcumin, an active component of turmeric (Curcuma longa), and its effects on health
Crit. Rev. Food Sci. Nutr.
The multifaceted role of curcumin in cancer prevention and treatment
Molecules
Effect of imatinib therapy with and without turmeric powder on nitric oxide levels in chronic myeloid leukemia
J. Oncol. Pharm. Pract.
Curcumin: a polyphenol with molecular targets for cancer control
Asian Pac. J. Cancer Prev.
Cited by (6)
Ponatinib: A comprehensive drug profile
2024, Profiles of Drug Substances, Excipients and Related MethodologyIn vitro biodistribution studies on clinically approved FGFR inhibitors ponatinib, nintedanib, erlotinib and the investigational inhibitor KP2692
2024, European Journal of Pharmaceutical SciencesSimple and affordable synchronous spectrofluorimetric determination of the natural anticancer polyphenols; resveratrol and curcumin in human plasma
2023, Spectrochimica Acta - Part A: Molecular and Biomolecular SpectroscopyA novel platform based on MnO<inf>2</inf> nanoparticles and carboxylated multi-walled carbon nanotubes composite for accurate and rapid determination of curcumin in commercial food products
2023, Journal of Food Composition and AnalysisCitation Excerpt :Therefore, establishment of a reliable and accurate method for the determination of curcumin is of great significance for its application in pharmacology and clinical medicine. Many analytical methods such as chromatography (Noori et al., 2022), synchronized spectrofluorimetry (Sharkasy et al., 2022), fluorescence (Hu et al., 2019), digital image colorimetry (Caleb and Alshana, 2021), spectrophotometry (Altunay et al., 2020), etc have been reported, for curcumin determination. However, the sensitivity of these methods is not high, and the operation is cumbersome.
Green analytical chemistry metrics and life-cycle assessment approach to analytical method development
2022, Green Chemical Analysis and Sample Preparations: Procedures, Instrumentation, Data Metrics, and SustainabilityFirst Electrochemical Approach to Voltammetric Behavior and Sensing of Anticancer Drug Ponatinib
2022, Journal of the Electrochemical Society